Treatment of aggressive non-Hodgkin's lymphomas;Behandlung aggressiver Non-Hodgkin-Lymphome

Internist

Volumn 38, Issue 2, 1997, Pages 135-142

  Kaiser, U ^a   Trumper L ^b   Pfreundschuh, M ^b   Havemann, K ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

CLASSIFICATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PROGNOSIS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; SURVIVAL RATE;

EID: 0031052243     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Aisenberg AC (1991) Malignant Lymphoma: Biology, Natural History, and Treatment. Philadelphia, London, Lea & Febiger
2. Armitage JO (1993) Treatment of non-Hodgkin's lymphomas. N Engl J Med 328:1023
3. Armitage JO, Fyfe MA, Lewis J (1984) Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 2:898
4. Armitage JO, Greer JP, Levine A et al. (1989) Peripheral T-cell lymphoma. Cancer 63:158
5. Armitage JO, Potter JF (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 32:269
6. Aviles A, Delgado S, Nambo MJ et al. (1994) Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiation Oncology Biol Phys 30:799
7. Beral V, Petermann T, Berkelmann R et al. (1991) AIDS-associated non-Hodgkin's lymphoma. Lancet 337:805
8. Brittinger G, Bartels H, Common H et al. (1986) Klinische und prognostische Relevanz der Kiel-Klassifikation der Non-Hodgkin-Lymphome. Onkologie 9:118
9. Darrington DL, Vose JM, Anderson JR et al. (1994) Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradio-therapy and autologous stemcell transplantation for lymphoid malignancies. J Clin Oncol 12:2527
10. Divine M, Lepage E, Briere J et al. (1996) Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case controlled analysis. J Clin Oncol 12:240
11. Engelhard M, Brittinger G, Dornoff W et al. (1996) High grade B-cell non-Hodgkin's lymphomas: Kiel classification is a significant prognostic factor. Ann Oncol 7:527
12. Engelhard M, Meusers P, Brittinger G, Theml H (1991) Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Am Oncol 2:177
13. Fanin R, Silvestri F, Geromin A et al. (1996) Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/-radiotherapy) and autologous bone marrow transplantation. Blood 87:11243
14. Fisher RI, Gaynor ER, Dahlberg S et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002
15. Fisher RI, Longo DL, DeVita VT et al. (1991) Long- term follow up of ProMACE-CytaBOM in non- Hodgkin's lymphomas. Ann Oncol 2:533
16. Fuller LM, Krasin MJ, Velasquez WS et al. (1995) Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiation Oncology Biol Phys 31:3
17. Gianni AM, Bregni M, Siena S et al. (1969) Is high- dose better than standard-dose chemotherapy as initial treatment of poor-risk large- cell lymphomas? A critical analysis from available randomized trials. Ann Oncol 7 (Suppl 3):12
18. Gisselbrecht C, Lepage E, Morel P et al. (1996) Short and intensified treatment with autologous stem cell transplantation versus ACVB regimen in poor prognosis aggressive lymphoma. Prognostic factors of induction failure. Ann Oncol 7 (Suppl 3):18
19. Glick JH, Kim K, Earle J et al. (1995) An ECOG randomized phase III trial of CHOP vs CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 14:391
20. Haioun C, Lepage E, Gisselbrecht C et al. (1994) Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 12:2543
21. Harris NL, Jaffe ES, Stein H et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361
22. Havemann K, Köppler H, Löffler M, Pfreundschuh M (1993) Integratives Konzept zur Behandlung hochmaligner Non-Hodgkin-Lymphome. Marburg und Homburg
23. Hudson BV, Hudson GV, Mac Lennan KA et al. (1994) Clinical stage I non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 69:1088
24. Jagannath S, Velasquez WS, Tucker SL et al. (1986) Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 4:859
25. Joos S, Otano-Joos MI, Ziegler S et al. (1996) Primary mediastinal B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87:1571
26. Kaiser U, Köppler H, Uebelacker I et al. (1996) Primary treatment of high grade NHL: Final analysis of a German multicenter trial. Ann Hematology 73 (SII):172
27. Köppler H, Pflüger KH, Eschenbach I et al. (1989) CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study. Br J Cancer 60:79
28. Köppler H, Pflüger KH, Eschenbach I et al. (1994) Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non- Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial. Ann Oncol 5:49
29. McKelvey EM, Gottlieb JA, Wilson HE (1976) Hydroxy-daunomycin (adriamycin) combination chemotherapy in malignant lymphomas. Cancer 38:1484
30. Meyer RM, Hryniuk WM, Goodyear MDE (1991) The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 9:339
31. Miller TP, Dalberg S, Cassady JR et al. (1996) Superiority of a brief course of CHOP plus radiotherapy (RT) over CHOP alone in localized unfavorable non-Hodgkin's lymphoma (NHL) is seen in lowest risk subgroups: a Southwest Oncology Group study. Ann Oncol 7 (Suppl 3):23
32. Monni O, Joensuu H, Franssila K et al. (1996) DNA copy number changes in diffuse large B-cell lymphoma - comparative genomic hybridization study. Blood 87:5269
33. Morel P, Lepage E, Brice P et al. (1992) Prognosis and treatment of lymphoblastic lymphoma in adult patients: a report on 80 patients. J Clin Oncol 10:1078
34. Nademanee A, Schmidt GM, O'Donnell MR et al. (1992) High dose chemoradiotherapy followed by autologous bone marrow trans-plantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 80:1130
35. O'Connell MJ, Harrington DP, Earle JD et al. (1987) Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma. J Clin Oncol 5:1329
36. Ozer H, for ASCO Ad Hoc CSF guideline expert panel (1994) American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471
37. Pettengell R, Crowther C (1994) Hemopoietic growth factors and dose intensity in high- grade and intermediate-grade lymphoma. Ann Oncol 5:S133
38. Pettengell R, Gurney H, Radford J et al. (1992) Granulocyte Colony-Stimulating Factor to prevent dose-limiting neutropenia in non- Hodgkin's lymphomas: A randomized controlled trial. Blood 80:1430
39. Pettengell R, Radford JA, Morgenstern GR et al. (1996) Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non- Hodgkin's lymphoma. J Clin Oncol 14:586
40. Renner Ch, Trümper L, Pfreundschuh M (1996) Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: Recent results and future prospects. Leuk 10:(in press)
41. Shipp MA (1996) Can we improve upon the International Index? Ann Oncol 7:S11
42. Shulman LN, Fisard B, Antin JH et al. (1993) Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. J Clin Oncol 11:937
43. Shulman LN und Mauch PM (1995) Current role of radiotherapy in Hodgkin's and non-Hodgkin's lymphoma. Current Opinion in Oncology 7:421
44. Sonneveld P (1995) The treatment of non- Hodgkin's lymphoma with mitoxantrone- containing regimens. Sem Oncol 22:29
45. Stauder R, Eisterer W, Thaler J, Günthert U (1995) CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 85:2885
46. Steinke B, Münz A, Mangegold C et al. (1994) Treatment intensification with r-metHuG- CSF in high grade malignant non-Hodgkin's lymphomas. Onkology 17:248
47. Stone RM, Neuberg D, Soiffer R et al. (1994) Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535
48. Sweetenham JW; Liberti G, Pearce R et al. (1994) High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European group for bone marrow transplantation. J Clin Oncol 12:1358
49. Tanosaki R, Okamoto S, Akatsuka N et al. (1994) Dose escalation of biweekly cyclophosphamid, doxorubicin, vincristin, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer 74:1939
50. The International Non-Hodgkin's Lymphoma Prognostic Factors Project, Shipp MA, Harrington DP, Anderson JR et al. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987
51. Trümper L, Renner Ch, Nahler M et al. (1994) Intensification of the CHOEP regimen for high- grade non-Hodgkin's lymphoma by G-CSF: Feasibility of a 14-day regimen. Onkologie 17:69
52. Uyl-de Grot CA, Hagenbeek A, Verdonck LF et al. (1995) Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma. Bone Marrow Transplant 16:463
53. van Besien KW, Mehra RC, Giralt SA et al. (1996) Allogenic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity, and survival depend on disease histology. Am J Med 100:299
54. Verdonck LF, van Putten WLJ, Hagenbeek A et al. (1995) Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045
55. Zinzani PL, Bendani M, Martelli M et al. (1996) Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 14:955
56. Zinzani PL, Martelli M, Storti S et al. (1995) Phase III comparative trial using CHOP vs. CIOP in the treatment of advanced-grade non-Hodgkin's lymphoma. Leukemia Lymphoma 19:32